FilingsTodayHome › Companies › Curiox Biosystems
Curiox Biosystems
큐리옥스바이오시스템즈 · 445680 · KOSDAQ
Filings, last 12 months
38
Supply contracts
1
Insider reports
9
Share & bond issues
0
At a glance
Curiox Biosystems filed 38 disclosures in the last 12 months, including 9 insider, 3 5% holder, 2 earnings and 1 contract. The most recent key filing was on Oct 30: CEO's holding fell by 570,000 sh (other change).
Revenue for 2025 was ₩5.2B, up 12.3% on 2024. It made an operating loss of ₩12.3B. Debt was 48% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩2.5B and operating loss of ₩7.7B.
Of 1 recent 5%+ holder report, 0 raised and 1 cut a stake; the largest stake reported was 13.84% on Oct 30.
Financial summary
2023
Revenue ₩6.8B
Op. profit -₩10.6B
Debt/equity 9%
2024
Revenue ₩4.6B
Op. profit -₩13.4B
Debt/equity 45%
2025
Revenue ₩5.2B
Op. profit -₩12.3B
Debt/equity 48%
2026 H1
Revenue ₩2.5B
Op. profit -₩7.7B
Debt/equity 9%
RevenueOperating profitOperating lossConsolidated where available · from periodic reports
5%+ holder reports
Key filings
10/29ContractSupply contract terminated
10/27EarningsLoss widenedOperating profit: loss widened (-₩2.7B → -₩4B). Revenue ₩1.5B, up 7.7% YoY.-₩4B
8/10InsiderInsider ownership report
8/105% holderReport of 5%+ holding
8/7InsiderInsider ownership report
8/6EarningsPreliminary operating results
4/175% holderReport of 5%+ holding
4/10InsiderInsider ownership report
4/10InsiderInsider ownership report
4/10InsiderInsider ownership report
4/10InsiderInsider ownership report
1/30InsiderInsider ownership report
1/2ExchangeUnfaithful disclosure
12/10ExchangeUnfaithful disclosure
12/2InsiderInsider ownership report
Other filings
10/1Annual report
10/1Annual report
10/1Annual report
8/14Half-year report
8/12Filing
8/11Filing
5/15Quarterly report
4/1Filing
3/31Filing
3/23Annual report
3/19Audit report
3/4Filing
12/12Filing
11/14Filing
11/14Quarterly report
Links open the original filing on DART, in Korean.